Some women climax into laughter, tears, or pain — and science is finally explaining why that doesn’t mean something is wrong.

OncoNano Medicine, Inc. ("OncoNano") today announced a research collaboration with Gilead Sciences, Inc. ("Gilead") to evaluate OncoNano's ON-BOARDtm encapsulation technology with Gilead's drug ...

The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in cancer treatment philosophy. Biomarker-guided therapy ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Paul P. Doghramji, MD, discusses the underdiagnosis of narcolepsy especially among younger individuals and how clinicians can address this.

Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, ...

- Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 - - Alixorexton Met the ...

Alkermes has reached an agreement to buy Avadel Pharma in a deal valued at up to $2.1 billion, claiming rights to an FDA-approved therapy for sleep disorder narcolepsy that has been predicted to make ...

Medical schools are training students in a form of care that the system can’t—or won’t—provide.

Looking back on 2025, Neda Shamie shares how a challenging monocular patient reinforced the importance of patience, presence, ...

Wealthy tech bro turned antivax crank Steve Kirsch attacked Paul Offit for refusing to debate antivaxxers, while Dr. Mike was "surrounded" by MAHA stans. These recent events led me to revisit the ques ...